Therapeutic advancement of chronic lymphocytic leukemia

Table 4 Phase 2 trials of ofatumumab monotherapy and chemoimmunotherapy in CLL patients

Reference (year)	Regimen	Number of patients	Treatment status	CR,%	ORR,%	Median PFS (months)	Median OS (months)
Wierda, 2010 [36]	Ofatumumab	95	FA-ref	0	51	5.5	14.2
		111	BF-ref	2	44	5.5	17.4
Flinn, 2011 [37]	Ofatumumab	42	Untreated	0	44	NR	NR
Wierda, 2011 [38]	O-FC (500 mg)	31	Untreated	32	77	NR	NR
	O-FC (1000 mg)	30	Untreated	50	73	NR	NR
Shanafelt, 2011 [39]	PCO	33	Untreated	45	94	NR	NR

Abbreviations: BF-ref, fludarabine-refractory CLL with bulky (>5 cm) lymphadenopathy; CR, complete response; FA-ref, fludarabine- and alemtuzumab-refractory; NR, not researched; O-FC (500 mg), 500 mg ofatumumab combined with fludarabine and cyclophosphamide; O-FC (1000 mg), 1000 mg ofatumumab combined with fludarabine and cyclophosphamide; ORR, overall response rate; OS, overall survival; PCO, pentostatin, cyclophosphamide and ofatumumab.

ISSN: 1756-8722